Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrecigenSTU:I5X -2.93%65 Days Inventory is 431.09 as of Mar. 2026, which is 226% above its 10-year median of 132.20. GuruFocus rates STU:I5X with a GF Score™ of 65/100 and a GF Value™ of €5.29 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 638 Biotechnology companies, Precigen ranks worse than 82.6% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Precigen's Average Total Inventories for the
three
months ended in Mar. 2026 was €10.46 Mil. Precigen's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €2.21 Mil.
Hence, Precigen's Days Inventory for the
three
months ended in Mar. 2026 was 431.09.
The historical rank and industry rank for Precigen's Days Inventory or its related term are showing as below:
STU:I5X'
s Days Inventory Range Over the Past 10 Years
Min: 18.77 Med: 132.2 Max: 1245.37
Current: 529.99
During the past 13 years, Precigen's highest Days Inventory was 1245.37. The lowest was 18.77. And the median was 132.20.
STU:I5X's Days Inventory is ranked worse than 82.6% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs STU:I5X: 529.99
Precigen's Days Inventory
increased
from Mar. 2025 (0.00) to Mar. 2026 (431.09).
It might indicate that Precigen's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Precigen's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.21.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Precigen's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.52.
Precigen (STU:I5X) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Precigen's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Precigen's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Precigen Days Inventory Related Terms
Precigen Days Inventory Historical Data
* Premium members only.
The historical data trend for Precigen's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:I5X vs KARD, SLBT, GENB: Days Inventory Comparison
For the Biotechnology subindustry, Precigen's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precigen Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precigen's Days Inventory distribution charts can be found below:
* The bar in red indicates where Precigen's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precigen (STU:I5X) has a Days Inventory of 431.09 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Precigen and its competitors. This is 226% above median its historical median of 132.20. Over the past decade, Precigen's Days Inventory has ranged from 18.77 to 1,245.37. According to the industry distribution chart, Precigen ranks #527 out of 638 companies in the Biotechnology industry, placing it in the top 82.6%.
Is Precigen's Days Inventory too high?
Precigen's current Days Inventory of 431.09 is 226% above median its 10-year median of 132.20. Over the past 10 years, this metric has ranged from a low of 18.77 to a high of 1,245.37. The Biotechnology industry median Days Inventory is 183.20. Precigen's value of 431.09 is 135.3% above this industry median. Based on the distribution chart, Precigen ranks #527 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Precigen has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Precigen's Days Inventory compare to KARD and SLBT?
According to the Biotechnology industry distribution chart, Precigen ranks #527 out of 638 companies for Days Inventory. This places Precigen in the lower half of its industry. The industry median Days Inventory is 183.20. Precigen's value of 431.09 is 135.3% above this benchmark. Historically, Precigen's own Days Inventory has ranged from 18.77 to 1,245.37 over the past decade. While the company's 10-year median is 132.20 vs. the industry median of 183.20, Precigen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precigen's current Days Inventory of 431.09 is 135.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Precigen and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precigen's current Days Inventory is 431.09, which is 226% above median its own 10-year median of 132.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precigen stock overvalued right now?
Based on GuruFocus' analysis, Precigen (STU:I5X) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.29, compared to a current price of €4.64 — trading 12.3% below its estimated fair value. The current Days Inventory is 431.09, which is 226% above median its 10-year median of 132.20 and 135.3% above the Biotechnology industry median of 183.20. Precigen's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Precigen (STU:I5X), the current Days Inventory is 431.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precigen (STU:I5X) Overvalued in 2026?
Based on GuruFocus' analysis, Precigen stock appears to be undervalued.
The current stock price of €4.64 is trading 12.3% below its estimated GF Value™ of €5.29.
GuruFocus considers Precigen to be Modestly Undervalued.
Key valuation signals for STU:I5X:
Days Inventory: 431.09 (226% above median its 10-year median of 132.20)
GF Value™: €5.29 vs. price of €4.64 (12.3% below fair value)
Industry Position: 135.3% above the Biotechnology median (#527 of 638)
No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
65GF Score
Get the complete analysis for STU:I5X
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:I5X has been successfully added to your 
